Beijing Beilu Pharmaceutical Co., Ltd. Class A

Beijing Beilu Pharmaceutical Co., Ltd. Class A

SSZSE:300016
7.40
CNY
-0.25
(-3.27%)
0.30EPS
33.45P/E
5.56BMarket Cap
Apr 27Next Earn

Total Valuation

CNY

As of September 30, 2026, Beijing Beilu Pharmaceutical Co., Ltd. Class A carries a market capitalization of 5.56B, placing it among publicly traded companies globally. Its enterprise value stands at 5.39B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap5.56B
Enterprise Value5.39B

Important Dates

Beijing Beilu Pharmaceutical Co., Ltd. Class A's next confirmed earnings release is scheduled for April 27, 2027.

Earnings Date4/27/2027

Share Statistics

As of September 30, 2026, Beijing Beilu Pharmaceutical Co., Ltd. Class A has 581.69M shares outstanding.

Shares Outstanding581.69M

Valuation Ratios

As of September 30, 2026, Beijing Beilu Pharmaceutical Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 33.45. The price-to-sales ratio is 3.91, and the price-to-book ratio stands at 2.23.

PE Ratio33.45
PS Ratio3.91
PB Ratio2.23
P/TBV Ratio2.41

Enterprise Valuation

As of September 30, 2026, Beijing Beilu Pharmaceutical Co., Ltd. Class A trades at an EV/EBITDA multiple of 26.28 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.87 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 26.28 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 5.39B versus a market cap of 5.56B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales3.87
EV / EBITDA26.28
EV / EBIT26.28

Financial Position

As of September 30, 2026, Beijing Beilu Pharmaceutical Co., Ltd. Class A maintains a current ratio of 2.86, meaning it holds 2.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 16.99, indicating elevated leverage, while an interest coverage ratio of 16.91 demonstrates strong ability to service its debt obligations.

Current Ratio2.86
Quick Ratio1.48
Debt / Equity16.99
Debt / EBITDA2.20
Interest Coverage16.91

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, Beijing Beilu Pharmaceutical Co., Ltd. Class A posted a return on equity (ROE) of 7.75, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 5.77 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 4.82, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 5.54, useful for judging operating efficiency across full business cycles. The company generates approximately 1.17M in revenue per employee across its workforce of 1,188.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.00 indicates how many times Beijing Beilu Pharmaceutical Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)7.75
Return on Assets (ROA)4.82
Return on Invested Capital (ROIC)5.77
Return on Capital Employed (ROCE)5.54
Revenue Per Employee1.17M
Employee Count1,188.00
Inventory Turnover2.00

Taxes

CNY

Over the twelve months ended September 30, 2026, Beijing Beilu Pharmaceutical Co., Ltd. Class A recorded 32.28M in income tax expense. That works out to an effective tax rate of 15.91, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 202.83M, leaving 162.46M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax32.28M
Effective Tax Rate15.91

Stock Price Statistics

CNY

As of the close on November 17, 2026, Beijing Beilu Pharmaceutical Co., Ltd. Class A's stock has declined approximately 16.67% over the past 52 weeks. The 50-day moving average sits at 8.38, while the 200-day moving average is 8.89.

52-Week Price Change-16.67%
50-Day Moving Average8.38
200-Day Moving Average8.89

Income Statement

CNY

Over the twelve months ended September 30, 2026, Beijing Beilu Pharmaceutical Co., Ltd. Class A generated 1.39B in revenue and converted that into 162.46M in net income, yielding earnings per share of 0.30. EBITDA reached 205.10M, while operating income came in at 174.55M.

Revenue1.39B
Gross Profit587.81M
Operating Income174.55M
Pretax Income202.83M
Net Income162.46M
EBITDA205.10M
EBIT205.10M
Earnings Per Share (EPS)0.30

Balance Sheet

CNY

As of September 30, 2026, Beijing Beilu Pharmaceutical Co., Ltd. Class A holds 790.16M in cash and equivalents against 452.01M in total debt, resulting in a net debt position of -174.02M. Total book value stands at 2.49B, with working capital of 995.99M providing operational flexibility.

Cash & Cash Equivalents790.16M
Total Debt452.01M
Net Debt-174.02M
Equity (Book Value)2.49B
Book Value Per Share4.29
Working Capital995.99M

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-141.39M

Margins

Over the twelve months ended September 30, 2026, Beijing Beilu Pharmaceutical Co., Ltd. Class A posted a gross margin of 42.25, reflecting its pricing power and cost economics. The operating margin of 12.55 and net profit margin of 11.68 provide insight into operational efficiency.

Gross Margin42.25
Operating Margin12.55
Pretax Margin14.58
Profit Margin11.68
EBITDA Margin14.74

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Beijing Beilu Pharmaceutical Co., Ltd. Class A paid dividends of 0.09 per share. The dividend payout ratio of 27.10 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield is negative at -0.21, meaning Beijing Beilu Pharmaceutical Co., Ltd. Class A raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Dividend Per Share0.09
Payout Ratio27.10
Shareholder Yield-0.21

Stock Splits

Beijing Beilu Pharmaceutical Co., Ltd. Class A's most recent stock split took place on September 4, 2018 with a 2:3 split ratio.

Last Split Date9/4/2018
Split Ratio2:3

Scores

As of September 30, 2026, Beijing Beilu Pharmaceutical Co., Ltd. Class A has an Altman Z-Score of 5.11, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score5.11